Literature DB >> 1456862

Treatment of cryptosporidiosis with paromomycin. A report of five cases.

K Armitage1, T Flanigan, J Carey, I Frank, R R MacGregor, P Ross, R Goodgame, J Turner.   

Abstract

Cryptosporidiosis continues to be one of the most devastating complications of the acquired immunodeficiency syndrome, causing severe, chronic diarrhea that is largely refractory to treatment. More than 60 drugs have been tried in the treatment of cryptosporidiosis, none of which have been consistently successful. We describe the successful treatment of cryptosporidiosis in five patients with acquired immunodeficiency syndrome with oral paromomycin at a dose of 1500 to 2000 mg/d. All five patients had resolution of symptoms and normalization of bowel movements, although one patient later relapsed while receiving paromomycin. Three of five patients cleared Cryptosporidium from the stool. Paromomycin is a promising therapy for cryptosporidiosis in acquired immunodeficiency syndrome and further prospective clinical trials are warranted.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456862

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  12 in total

1.  Human intestinal and biliary cryptosporidiosis.

Authors:  Xian-Ming Chen; Nicholas F LaRusso
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

Review 2.  Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs.

Authors:  O Kayser; C Olbrich; S L Croft; A F Kiderlen
Journal:  Parasitol Res       Date:  2002-12-11       Impact factor: 2.289

Review 3.  Parasitic infections of the small intestine.

Authors:  J Jernigan; R L Guerrant; R D Pearson
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

4.  Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model.

Authors:  R Verdon; J Polianski; C Gaudebout; C Marche; L Garry; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

5.  Putative anticryptosporidial agents tested with an immunodeficient mouse model.

Authors:  G J Leitch; Q He
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 6.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice.

Authors:  M W Riggs; V A Cama; H L Leary; C R Sterling
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study.

Authors:  R Mancassola; J M Reperant; M Naciri; C Chartier
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model.

Authors:  R Verdon; J Polianski; C Gaudebout; C Marche; L Garry; C Carbon; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin.

Authors:  S Tzipori; W Rand; J Griffiths; G Widmer; J Crabb
Journal:  Clin Diagn Lab Immunol       Date:  1994-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.